Introduction {#sec1-2055217320918619}
============

Delayed-release dimethyl fumarate (DMF) is approved for patients with relapsing--remitting multiple sclerosis (RRMS).^1^ As of January 31, 2020, \>445,000 patients have been treated with DMF, representing \>875,000 patient-years of exposure. Of these, 6,335 patients (14,241 patient-years) were from clinical trials. In patients treated with DMF, absolute lymphocyte count (ALC) decline typically occurs during the first year and then plateaus.^[@bibr2-2055217320918619]^ Early drops in ALC are not indicative of clinical response^[@bibr2-2055217320918619][@bibr3-2055217320918619]--[@bibr4-2055217320918619]^ but have been associated with subsequent development of severe prolonged lymphopenia.^[@bibr2-2055217320918619]^

The main objective of this study was to evaluate changes in ALC and CD4+/CD8+ T-cell subtypes in patients with RRMS receiving DMF in routine practice. A third of patients enrolled previously received natalizumab (NAT); NAT's mechanism of action typically leads to an increase in ALC, so we investigated the impact of prior NAT treatment on ALC and CD4+/CD8+ T-cell counts. We also investigated the impact of age (≤50 vs \>50 years) on DMF-associated changes in ALC and CD4+/CD8+ cell count, given that immunosenescence may lead to lymphopenia.

Materials and methods {#sec2-2055217320918619}
=====================

Study design {#sec3-2055217320918619}
------------

REALIZE (NCT02519413) was a retrospective, observational study conducted at nine sites in the USA, collecting data via medical chart abstraction at a single timepoint.

Patients and exclusion/inclusion criteria {#sec4-2055217320918619}
-----------------------------------------

Eligible patients initiated DMF treatment on/after 27 March 2013 and received ≥6 months' continuous DMF treatment. Other inclusion criteria: aged ≥18 years; diagnosis of relapsing multiple sclerosis (MS); measurement for ALC, CD4+ count, and CD8+ count at baseline; and ≥1 subsequent timepoint while receiving DMF for ≥6 months. Key exclusion criteria: diagnosis of human immunodeficiency virus/acquired immunodeficiency syndrome and participation in DMF phase 3 studies.^[@bibr3-2055217320918619],[@bibr4-2055217320918619]^

Endpoints {#sec5-2055217320918619}
---------

The primary endpoint was estimated adjusted change from baseline in ALC, CD4+ count, and CD8+ count at 6-month intervals within 12 months of DMF initiation. Secondary endpoints assessed at 6 and 12 months following DMF initiation were absolute counts; change from baseline and percentage change from baseline for lymphocytes and CD4+:CD8+ ratio; time to predetermined lymphocyte counts; and potential predictors of low lymphocyte counts.

Exploratory endpoints included ALC, CD4+ and CD8+ counts, and CD4+: CD8+ ratio; incidence of opportunistic and serious infections; reasons for DMF discontinuation; and average time to recovery to baseline values among patients with ALC, CD4+ count, or CD8+ count less than baseline count, and less than the lower limit of normal (LLN) after DMF cessation.

Safety endpoints {#sec6-2055217320918619}
----------------

Data on serious and opportunistic infections were captured by the healthcare provider or designated personnel performing chart abstraction. For opportunistic infections, a list of potential opportunistic infections was provided or direction was given remotely. For serious infections, instructions were given to sites to review the medical record and capture the infection if it was noted as serious (e.g. requiring extensive treatment or denoted as severe). The study management and pharmacovigilance teams reviewed infection data and queried any information necessary for proper assessment of type of infection.

Statistical analysis {#sec7-2055217320918619}
--------------------

Primary and secondary endpoint analyses were performed on the full analysis population, including all eligible enrolled patients with an approved waiver of informed consent. For the primary analysis of ALC, CD4+ count, and CD8+ count, the change from baseline at months 6 and 12 was estimated using a repeated-measures mixed-effects model (RMMM); model covariates included baseline ALC, study day (log transformed), and baseline value by study day interaction. Study day was included as a random effect. Percentage change from baseline was estimated at months 6 and 12, as prespecified, and at 15 months after DMF initiation.

For secondary endpoint analysis, absolute counts, change from baseline, and percentage change from baseline to months 6 and 12 were summarized for total lymphocytes, CD4+ and CD8+ cells, and CD4+: CD8+ ratio. Assessments were only included in the 6 and 12 month tabulation if they were obtained ±30 days from the target timepoint (180 days from DMF initiation for month 6, 360 days from DMF initiation for month 12).

Logistic regression assessed whether age at baseline (≤50 vs \>50 years), baseline ALC, and study site were associated with lymphopenia at months 6 and 12. Association between baseline predictors, percentage change, and absolute change from baseline ALC at months 6 and 12 was assessed by an analysis of covariance model (rank-transformed).

Post-hoc analyses explored trends in patients with/without prior NAT exposure, defined as NAT infusion within 180 days of DMF initiation. Using a RMMM specified for the primary analysis, ALC changes were estimated for patients with/without prior NAT exposure. Kaplan-Meier analyses of time to ALC \<0.8 × 10^9^/l or \<0.5 × 10^9^/l were conducted by prior NAT exposure in patients with a baseline ALC of ≥0.8 × 10^9^/l (*n* = 459) or ≥0.5 ×10^9^/l (*n* = 468), respectively. The Cox proportional hazards model assessed whether prior NAT exposure was associated with an increased risk of low ALC (\<0.8 × 10^9^/l or \<0.5 × 10^9^/l), adjusting for age at DMF initiation and baseline ALC.

The Pearson correlation statistic assessed association between ALC and CD4+/CD8+ counts by age (≤50 vs \>50 years).

Safety analysis {#sec8-2055217320918619}
---------------

Safety data analyses summarized the incidence of serious and opportunistic infections using descriptive statistics.

Results {#sec9-2055217320918619}
=======

Patient demographics {#sec10-2055217320918619}
--------------------

In total, 483 patient charts were abstracted; 476 patients were included in the full analysis population ([Table 1](#table1-2055217320918619){ref-type="table"}). Seven patients were excluded post-hoc: five owing to missing data on DMF discontinuation, and two owing to inconsistencies in reported laboratory values. Most patients were female (73%) and white (73%). On average, patients were aged ∼49 years, almost a decade older than patients in pivotal trials.^[@bibr3-2055217320918619],[@bibr4-2055217320918619]^ Of 476 patients with ≥1 treatment period value, 475, 291, 233, and 173 patients had an assessment ≥6, ≥12, \>15, and ≥18 months, respectively, after DMF initiation.

###### 

Patient baseline demographics.

![](10.1177_2055217320918619-table1)

  Characteristic                                                Total patients(*n* = 476)   Patients with prior NAT exposure(*n* = 132)   Patients without prior NAT exposure(*n* = 344)
  ------------------------------------------------------------- --------------------------- --------------------------------------------- ------------------------------------------------
  Female, *n* (%)                                               349 (73)                    92 (70)                                       257 (75)
  Age, mean (SD), years                                         49 (11.0)                   50.2 (10.6)                                   48.4 (11.4)
   18--29, *n* (%)                                              17 (4)                      2 (2)                                         15 (4)
   30--39, *n* (%)                                              91 (19)                     23 (17)                                       68 (20)
   40--49, *n* (%)                                              135 (28)                    39 (30)                                       96 (28)
   50--59, *n* (%)                                              149 (31)                    42 (32)                                       107 (31)
   ≥60, *n* (%)                                                 84 (18)                     26 (20)                                       58 (17)
  Race, *n* (%)                                                                                                                           
   White                                                        346 (73)                    104 (79)                                      242 (70)
   Black or African American                                    35 (7)                      16 (12)                                       19 (6)
   Other                                                        21 (4)                      6 (5)                                         15 (4)
   Not reported owing to confidentiality                        74 (16)                     6 (5)                                         68 (20)
  Prior MS treatment, *n* (%)                                   344 (72)                    132 (100)                                     212 (62)
  Prior MS treatment type, *n* (%)                                                                                                        
   NAT^[a](#table-fn2-2055217320918619){ref-type="table-fn"}^   138 (29)                    132 (100)                                     6 (2)
   Glatiramer acetate                                           66 (14)                     4 (3)                                         62 (18)
   Methylprednisolone                                           60 (13)                     18 (14)                                       42 (12)
   Interferon                                                   83 (17)                     3 (2)                                         80 (23)
   Methylprednisolone sodium succinate                          27 (6)                      2 (2)                                         25 (7)
   Teriflunomide                                                13 (3)                      1 (\<1)                                       12 (3)
   Fingolimod                                                   13 (3)                      0                                             13 (4)
   Other                                                        31 (7)                      3 (2)                                         28 (8)

MS: multiple sclerosis; NAT: natalizumab; SD: standard deviation.

^a^Prior MS treatment included at any treatment prior to initiating dimethyl fumarate; patients were categorized as "prior NAT" or "no prior NAT" based on NAT exposure within 6 months of initiating dimethyl fumarate.

Estimated change in ALC, CD4+ count, and CD8+ count from baseline {#sec11-2055217320918619}
-----------------------------------------------------------------

Estimated means for ALC, CD4+ count, and CD8+ count declined over the study following DMF initiation from baseline to months 6 and 12. The largest declines were observed during the first 6 months, with slower rates of decline through month 15. Mean baseline ALC (2.23*×*10^9^/l) decreased by ∼39% (95% confidence interval (CI): --41.1 to --37.2) by month 6 and 44% (95% CI: --46.6 to --42.1) by month 12 ([Table 2](#table2-2055217320918619){ref-type="table"}). Mean baseline CD4+ count (1.06*×*10^9^/l) decreased by ∼37% (95% CI: --39.3 to --35.1) by month 6 and 42% (95% CI: --44.5 to --39.8) by month 12. Mean baseline CD8+ count (0.50*×*10^9^/l) decreased by ∼47% (95% CI: --49.0 to --44.1) by month 6 and 53% (95% CI: --55.5 to --49.9) by month 12 ([Table 2](#table2-2055217320918619){ref-type="table"}).

###### 

Percentage change in absolute lymphocyte count (ALC), CD4+ count, and CD8+ count.

![](10.1177_2055217320918619-table2)

              Mean, ×10^9^/l^[a](#table-fn4-2055217320918619){ref-type="table-fn"}^ (*n* = 476)   Mean % changefrom baseline^[a](#table-fn4-2055217320918619){ref-type="table-fn"}^
  ----------- ----------------------------------------------------------------------------------- -----------------------------------------------------------------------------------
  ALC                                                                                             
   Baseline   2.23                                                                                
   Month 6    1.36 (1.31--1.40)                                                                   --39 (--41.1-- --37.2)
   Month 12   1.24 (1.19--1.29)                                                                   --44 (--46.6-- --42.1)
   Month 15   1.20 (1.15--1.25)                                                                   --46 (--48.3-- --43.7)
  CD4+                                                                                            
   Baseline   1.06                                                                                
   Month 6    0.67 (0.64--0.69)                                                                   --37 (--39.3-- --35.1)
   Month 12   0.61 (0.59--0.64)                                                                   --42 (--44.5-- --39.8)
   Month 15   0.60 (0.57--0.62)                                                                   --44 (--46.2-- --41.3)
  CD8+                                                                                            
   Baseline   0.50                                                                                
   Month 6    0.27 (0.25--0.38)                                                                   --47 (--49.0-- --44.1)
   Month 12   0.24 (0.22--0.25)                                                                   --53 (--55.5-- --49.9)
   Month 15   0.23 (0.21--0.24)                                                                   --55 (--57.6-- --51.8)

Mean values at months 6, 12, and 15 were estimated using a repeated-measures mixed-effects model with baseline ALC, time (log-transformed), and baseline ALC×time interaction effect. Time (log-transformed) was a random effect. Percentage change was estimated from baseline and the estimated mean change.

^a^Values in parentheses represent mean 95% confidence intervals.

Changes in ALC, and CD4+/CD8+ T-cell subsets assessed using raw data, were consistent with estimates from the RMMM ([Figure 1(a)--(c)](#fig1-2055217320918619){ref-type="fig"}). ALC positively correlated with CD4+ and CD8+ at baseline and at months 9--15 in both younger (≤50) and older (\>50) patients (*r*\>0.744 for all correlations, *p*\<0.0001). Patients with low ALC also had low CD4+ and CD8+ counts. Among 46 patients with the lowest post-baseline ALC of \<0.5 × 10^9^/l during treatment, all had the lowest post-baseline CD4+ and CD8+ counts of \<0.4 × 10^9^/l and \<0.2 × 10^9^/l, respectively.

![Observed (a) absolute lymphocyte count (ALC), (b) CD4+ count, and (c) CD8+ count over time. Change from baseline ALC was estimated using repeated-measures mixed-effects model analysis.](10.1177_2055217320918619-fig1){#fig1-2055217320918619}

Prior NAT exposure {#sec12-2055217320918619}
------------------

Approximately one-third of the patient population were previously treated with NAT. Mean age was similar in both cohorts. Consistent with NAT's mechanisms of action, median ALC values for patients with prior NAT exposure were higher at baseline vs patients without (2.90 × 10^9^/l vs 1.97 × 10^9^/l; [Table 3](#table3-2055217320918619){ref-type="table"}). Although relative percentage reduction from initial ALC was greater in patients with prior NAT exposure (decrease of 51.3% at month 6) than in patients without (decrease of 32.1% at month 6), both reached a similar mean at month 6 (1.41 × 10^9^/l vs 1.34 × 10^9^/l, respectively), maintained through month 15 ([Table 3](#table3-2055217320918619){ref-type="table"}). Despite the higher relative reduction, 50% of patients with prior exposure to NAT remained ≥LLN (0.91 × 10^9^/l) during 12 months of DMF treatment.

###### 

Percentage change in absolute lymphocyte count (ALC) by prior natalizumab (NAT) exposure.

![](10.1177_2055217320918619-table3)

             Patients with prior NAT exposure   Patients without prior NAT exposure                       
  ---------- ---------------------------------- ------------------------------------- ------------------- --------
  Baseline   2.90                                                                     1.97                
  Month 6    1.41 (1.34--1.48)                  --51.3                                1.34 (1.29--1.39)   --32.1
  Month 12   1.21 (1.13--1.29)                  --58.2                                1.25 (1.19--1.31)   --36.4
  Month 15   1.15 (1.07--1.23)                  --60.4                                1.22 (1.16--1.29)   --37.8

^a^Values in parentheses represent mean 95% confidence intervals.

^b^Up to 180 days prior to dimethyl fumarate (DMF), 132 patients received NAT (two patients received NAT \>180 days prior to DMF and were excluded from the analysis).

^c^Mean values at months 6, 12, and 15 were estimated using a repeated-measures mixed-effects model with baseline ALC, time (log-transformed), and baseline ALC×time interaction effect. Time (log-transformed) was a random effect. Percentage change was estimated from baseline and the estimated mean change.

Similar to these results for ALC, prior NAT exposure influenced the initial decline of CD4+ and CD8+ counts from baseline to 6 months. Mean CD4+ T-cell counts in patients without prior NAT exposure vs those with prior NAT exposure decreased by 33% vs 46% at month 6 and 37% vs 52% at month 12, respectively. Likewise, mean CD8+ T-cell counts in patients without prior NAT exposure vs those with prior NAT exposure decreased by 40% vs 57% at month 6 and 46% vs 65% at month 12, respectively. Although the relative percentage reductions from initial CD4+ and CD8+ counts were greater in patients with prior NAT exposure than in patients without, both groups demonstrated similar mean CD4+ and CD8+ counts at month 6 (CD4+: 0.68*×*10^9^/l vs 0.66*×*10^9^/l, respectively; CD8+: 0.27*×*10^9^/l vs 0.26*×*10^9^/l, respectively) and at month 12 (CD4+: 0.60*×*10^9^/l vs 0.62*×*10^9^/l, respectively; CD8+: 0.23*×*10^9^/l vs 0.24*×*10^9^/l, respectively).

Prior NAT exposure influenced the kinetics of initial ALC decline, but neither increased nor decreased the risk of subsequent development of lymphopenia upon initiation of DMF. In a Cox proportional hazards model adjusted for baseline ALC and age (≤50 vs \>50 years), the hazard ratio of patients with and without prior NAT exposure experiencing an ALC \<0.8 × 10^9^/l while receiving DMF was 1.180 (95% CI: 0.793 to 1.727; *p = *0.4048). Similarly, the hazard ratio for experiencing an ALC \<0.5 × 10^9^/l was 1.247 (95% CI: 0.612 to 2.446; *p = *0.5304).

Age {#sec13-2055217320918619}
---

At 6 months following initiation of DMF, 25% (18/72) of patients aged ≤50 years had an ALC \<LLN and 29% (19/65) of patients aged \>50 years had an ALC \<LLN (odds ratio (OR) = 1.24; *p* = 0.7003; Table 4). At this time, there was no difference in the median percentage change from baseline ALC in patients aged ≤50 years vs patients aged \>50 years (--40.3% vs --45.5%; *p* = 0.1253). At month 12, 29% (15/51) of patients aged ≤50 years at baseline had an ALC \<LLN compared with 50% (33/66) of patients aged\> 50 years (OR = 2.38; *p* = 0.0366; Table 4). Median percentage change from baseline ALC in patients aged ≤50 years was smaller than in patients aged \>50 years (−40.0% vs −55.7%; *p* = 0.0102) at 12 months.

###### 

Association between age and absolute lymphocyte count (ALC) \<LLN at months 6 and 12.

![](10.1177_2055217320918619-table4)

                            *n*          Category               *n/N* (%) \<LLN   OR^[a](#table-fn10-2055217320918619){ref-type="table-fn"}^   Predictor *p*-value^[b](#table-fn11-2055217320918619){ref-type="table-fn"}^
  ------------------------- ------------ ---------------------- ----------------- ------------------------------------------------------------ -----------------------------------------------------------------------------
  Month 6                                                                                                                                      
   Baseline ALC             137          Continuous predictor                     0.51                                                         0.0106
   Age at baseline, years   137          ≤50                    18/72 (25)        1.24                                                         0.7003
  \>50                      19/65 (29)                                                                                                         
  Month 12                                                                                                                                     
   Baseline ALC             117          Continuous predictor                     0.78                                                         0.2154
   Age at baseline, years   117          ≤50                    15/51 (29)        2.38                                                         0.0366
  \>50                      33/66 (50)                                                                                                         

LLN: lower limit of normal; OR: odds ratio.

Analysis is restricted to patients with an ALC  ≥ 0.91 × 10^9^/l at baseline. Exact logistic regression analysis methods applied; *p*-values are from exact conditional tests. For categorical predictor variables, the first category is the reference category.

^a^The OR is the increase in odds of having an event with an increase in baseline ALC of 1.0 × 10^9^/l.

^b^The *p*-value evaluates the association between ALC \<LLN at the timepoint and each predictor variable.

Results were similar when evaluating change in ALC. Interpretation of results from both analyses is limited by the small number of patients with measurements 6 and 12 months after treatment initiation.

Baseline ALC {#sec14-2055217320918619}
------------

Baseline ALC correlated with an ALC \<LLN at month 6 (OR = 0.51, *p = *0.0106 with each increase in baseline ALC of 1.0 × 10^9^/l), and the percentage change from baseline at months 6 and 12.

DMF discontinuation and lymphocyte recovery after DMF discontinuation {#sec15-2055217320918619}
---------------------------------------------------------------------

In total, 114 (24%) patients discontinued DMF after an average of 1.3 years of treatment. Forty patients discontinued for reasons associated with low lymphocyte or blood counts (13 of these were aged ≤50 years and 27 were aged \>50 years).

Of 114 patients who discontinued DMF, 29% had ≥1 ALC \<0.91 × 10^9^/l while receiving treatment and \>2 months after DMF discontinuation. Among these, 55% (16/29) had ALC values ≥0.91 × 10^9^/l after discontinuation, and mean (standard deviation) time for receiving DMF treatment before discontinuation of 414 (198) days. While receiving DMF treatment, 23 of 29 patients experienced an ALC \<0.8 × 10^9^/l and six of 29 experienced an ALC \<0.5 × 10^9^/l ([Figure 2](#fig2-2055217320918619){ref-type="fig"}). Of 29 patients with ≥1 ALC \<0.91 × 10^9^/l during DMF treatment and \>2 months after DMF discontinuation, three initiated NAT and two initiated fingolimod following DMF discontinuation; of 25 patients who did not initiate NAT or fingolimod after DMF discontinuation, 12 had ALC values \>0.91 × 10^9^/l.

![Individual absolute lymphocyte count (ALC) values before and after delayed dimethyl fumarate (DMF) discontinuation and regression line. The regression line was calculated by locally estimated scatterplot smoothing with linear interpolation.](10.1177_2055217320918619-fig2){#fig2-2055217320918619}

Safety: adverse events {#sec16-2055217320918619}
----------------------

Since this was a retrospective chart review, adverse event incidence and severity could not be accurately determined. Commonly reported infections included urinary tract infection, respiratory infections, and varicella zoster. There was no pattern of infection type among the few patients who experienced a possible opportunistic or serious infection (*n* = 7 (1%) in the 6 months prior to DMF treatment; *n* = 38 (8%) during DMF treatment; and *n* = 6 (5%) in the 6 months after DMF treatment). The most common infections during DMF treatment were urinary tract infections (*n* = 13), upper respiratory infections (*n* = 9), lower respiratory infections (*n = *5), and varicella zoster (*n* = 4). There were no significant associations between ALC, CD4+ count, CD8+ count, and occurrence of possible opportunistic or serious infections for any time period (prior to, during, or after DMF treatment).

Discussion {#sec17-2055217320918619}
==========

The effect of DMF on ALC decline during early treatment has been assessed in several studies.^[@bibr2-2055217320918619],[@bibr5-2055217320918619][@bibr6-2055217320918619][@bibr7-2055217320918619][@bibr8-2055217320918619][@bibr9-2055217320918619]--[@bibr10-2055217320918619]^ In integrated analyses of phase 2b/3 extension studies, mean ALC decreased during the first year, then plateaued, remaining ≥LLN (0.91 × 10^9^/l).^[@bibr2-2055217320918619]^ Among those treated for ≥6 months (*n = *2099), ALCs remained ≥LLN in 84% and 76% of patients after 6 and 12 months, respectively, and were within normal range at all visits in 61% of patients evaluated. Lowest post-baseline lymphopenia was \<LLN to ≥0.800 × 10^9^/l in 9%, \<0.800 × 10^9^/l to 0.500 ×10^9^/l in 21%, \<0.500 × 10^9^/l to 0.200 × 10^9^/l in 7%, and \<0.200 × 10^9^/l in \<1% of patients overall.

Very rare cases of progressive multifocal leukoencephalopathy have occurred in patients treated with DMF in the clinical trial and post-marketing setting, predominantly in the context of moderate (≥0.5 ×10^9^/l to \<0.8 × 10^9^/l) to severe (\<0.5 × 10^9^/l) lymphopenia persisting for ≥6 months; one case occurred in a patient with mild lymphopenia.^[@bibr1-2055217320918619]^ Prescribing guidelines vary according to local labels, but all recommend monitoring lymphocyte levels and considering discontinuing DMF for patients with an ALC \<0.5 × 10^9^/l persisting for ≥6 months.^[@bibr1-2055217320918619]^ Thus, it is important to characterize ALC profiles in patients with MS during and after treatment with DMF, especially in the real-world setting of routine clinical practice.

We found that ALC dynamics over the first year of DMF treatment were generally consistent with clinical trial observations and other real-world data.^[@bibr2-2055217320918619],[@bibr11-2055217320918619]^ CD4+ and CD8+ T-cell subsets strongly correlated with ALC; decreases from baseline were more pronounced in the first 6 months of treatment than months 6--12. A greater reduction in mean ALC after 12 months of DMF was observed (44%) than reported by Fox et al. (30%).^[@bibr2-2055217320918619]^ This was likely influenced by the difference in the proportion of patients who had received prior NAT treatment, known to increase the number of circulating lymphocytes.^[@bibr12-2055217320918619]^ Patients with prior NAT treatment had on average a higher baseline ALC compared with patients without prior NAT treatment. Over the course of the study, there were no differences in mean ALC values at months 6, 12, and 15 between patients with prior NAT treatment and those without. Previous NAT treatment was not found to be a risk factor for lymphopenia upon subsequent initiation of DMF. In addition, in a recently published study of patients with RRMS who switched from NAT to DMF treatment (STRATEGY), no new major adverse events were reported compared with what is already known about the safety profile of DMF.^[@bibr13-2055217320918619]^

Our study demonstrated a more pronounced decline in CD8+ T cells than in CD4+ T cells. Others have suggested that such decline is driven by CD8+ memory cells rather than naive T cells.^[@bibr5-2055217320918619],[@bibr14-2055217320918619]^ Although the clinical relevance of DMF-associated decline in memory CD8+ T cells remains unclear, activated CD8+ T cells seem to play a role in the demyelination of axons in MS lesions.^[@bibr15-2055217320918619]^ In \>2500 patients receiving DMF for a median (range) of 5.7 (0.1--8.3) years in the ENDORSE long-term safety study,^[@bibr16-2055217320918619]^ those with severe prolonged lymphopenia (2% (*n* = 53)) did not present with an increased incidence of serious infections, herpes infections or with malignancies and continued treatment after becoming severely lymphopenic for a total median (range) of 34 (4--81) months before discontinuing.^[@bibr16-2055217320918619]^

REALIZE also assessed the impact of age on the risk of developing DMF-associated lymphopenia. The pattern of lymphocyte decline was generally similar across age groups; however, older age (≥50 years) was associated with an increase in median percentage decline in ALC at month 12 compared with younger age (\<50 years). This association was not observed at month 6. Although the incidence of ALCs \<LLN was higher in patients aged ≥50 years, it should be noted that both younger and older patients experienced ALCs \<LLN (0.91 × 109/l). Of note, older age in general is associated with immunosenescence, characterized by decreased levels and functionality of B and T lymphocytes.17 The clinical significance of these findings in the context of DMF treatment is unclear; this study was not powered to determine if there was an increased risk of prolonged lymphopenia (\>6 months duration) in older patients.

Assessment of ALC recovery kinetics and predictors in patients with lymphopenia who discontinued DMF treatment was challenging, owing to the low number of patients who discontinued the study because of low ALCs (who also had follow-up ALCs in the absence of other disease-modifying therapies). However, among the small number available for evaluation, at ≥2 months after DMF discontinuation ALC values returned to \>0.91 ×10^9^/l (\<LLN) in nearly half of patients (12/25). Interestingly, a recently published article by Chan et al. reports an analysis of patients from clinical trials and real-world clinical care, showing that the majority of patients who discontinued DMF due to lymphopenia experienced ALC reconstitution within 2--4 months following DMF discontinuation.^[@bibr18-2055217320918619]^

The strengths of this study include the use of observational data from routine clinical care and the availability of baseline ALC assessments; however, there are limitations with retrospective studies. Data collection was limited to routinely recorded information and information on laboratory values, as well as potential confounders, may not have been consistently recorded. Furthermore, although sites were provided with a list of possible opportunistic infections and guidance on how to record serious infections, the decision to record a safety event as a possible opportunistic or serious infection was at the discretion of the healthcare provider. Nevertheless, our results are consistent with previous studies that have evaluated changes in circulating immune cells from 6 months to 2 years.^[@bibr9-2055217320918619],[@bibr10-2055217320918619],[@bibr14-2055217320918619],[@bibr19-2055217320918619]^

In summary, our data from real-world clinical practice support the results of previous clinical trials in demonstrating that DMF-associated decline in ALC in the first 12 months of treatment is closely correlated with decline in CD4+ and CD8+ T cells, independent of prior NAT treatment. ALC monitoring continues to be an effective strategy to identify patients who may be at risk of prolonged lymphopenia over the first year of DMF treatment, irrespective of age. These results may help guide clinicians in managing patients at risk of lymphopenia during DMF treatment.
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